
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
MAD2L1BP (MAD2L1 binding protein) encodes a protein that interacts with MAD2L1, a core component of the spindle assembly checkpoint. By associating with MAD2L1, MAD2L1BP may participate in coordination of checkpoint signaling and cell-cycle events during late mitosis. Its potential role in regulating the transition from chromosome alignment to anaphase links MAD2L1BP to mechanisms that help ensure accurate chromosome segregation, although its precise molecular function remains incompletely characterized.
PANC-1 is a human pancreatic ductal adenocarcinoma cell line established from a pancreatic carcinoma of ductal origin from a 56-year-old male patient. The cell line represents a pancreatic cancer model and is widely used in studies of pancreatic tumor biology, cancer signaling pathways, and therapeutic response mechanisms.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?